Merck completes expansion of Madrid Gonal-f API plant

Merck completes expansion of Madrid Gonal-f API plant

The German drug manufacturer announced it had finished work on the €15m expansion of the facility in the Madrid municipality Tres Cantos this week.Simon Sturge, Chief Operating Officer of Merck’s biopharma business, cited increasing demand for the firm’s “core portfolio of medicines” as a driver for the investment.The Madrid site is already the main global production hub for the active pharmaceutical ingredients for Merck’s fertility treatment Gonal-f and growth hormone disorders treatment Saizen.DemandDemand for Gonal-f has increased in recent months. According to Merck’s Q2 financial results the drug generated revenue of €209m in the second quarter, which is an increase of 23% on the year earlier period.Around 75% of this growth came from the North America, which Merck said was a result of “a continued advantageous competitive situation.”Merck’s product ha…

Be the first to comment on "Merck completes expansion of Madrid Gonal-f API plant"

Leave a comment

Your email address will not be published.